Quality & complianceOfficial

Denmark flags supply problems with Neurontin 600 mg tablets from Viatris until mid-December

🇩🇰 DKMA · Tue 27 Oct 2026

The Danish Medicines Agency says higher demand is behind disruption to Viatris ApS's gabapentin 600 mg film-coated tablets, with supply expected to be affected from late August to mid-December 2026.

The Danish Medicines Agency (DKMA) has published a supply notice for Neurontin 600 mg film-coated tablets marketed by Viatris ApS. The agency says there are current problems with supply of the product, which contains the active substance gabapentin (ATC code N02BF01).

DKMA gives the expected period of disruption as late August to mid-December 2026. The notice was first published on 23 October 2026 and updated on 27 October 2026.

The stated cause is increased sales and demand. The notice does not say how many packs are affected, whether other strengths or presentations are involved, or what alternatives are recommended.

DKMA directs questions about the current status to the company. The notice appears in the agency's section for supply announcements on medicines.

What it means for your team

  • Supply and market-access teams in Denmark should note the disruption window of late August to mid-December 2026 when planning availability of gabapentin 600 mg.
  • The cause is given as higher demand rather than a quality or safety issue, though the notice offers no further detail.
  • Up-to-date availability information must come from Viatris ApS, as DKMA refers status queries to the company.
  • The notice contains no guidance on alternatives, so teams should consult DKMA's wider supply resources if they need that information.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →